1Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology,1998,27:35-41.
2Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology,2002,36:941-948.
3Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology,2002,36:374-380.
4Angeli P, Volpin R, Gerunda G, et al. Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology,1999,29:1690-1697.
5Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology,1998,28:416-422.
6Brensing KA, Textor J, Strunk H, et al. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet,1997,349:697-698.
7Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl,2000,6:277-286.
